Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO)

Historical Holders from Q4 2023 to Q2 2025

Symbol
LXEO on Nasdaq
CUSIP
52886X107
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
55.6M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
42.3M
Holdings value
$170M
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
90
Number of buys
52
Number of sells
-32
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BALYASNY ASSET MANAGEMENT L.P. 9.99% $39.4M 8.35M Balyasny Asset Management L.P. Jun 30, 2025
CITADEL ADVISORS LLC 9.6% $25.2M 5.33M Kenneth Griffin Jun 30, 2025
Affinity Asset Advisors, LLC 7.75% $20.1M 4.25M Affinity Healthcare Fund, LP May 28, 2025
JANUS HENDERSON GROUP PLC 11.1% -18.6% $17.4M -$4.12M 3.68M -19.2% JANUS HENDERSON GROUP PLC Jun 30, 2025
Vestal Point Capital, LP 6% $15.2M 3.23M Vestal Point Capital, LP Jun 30, 2025
Frazier Life Sciences Public Fund, L.P. 5.7% $14.5M 3.07M Frazier Life Sciences Public Fund, L.P. Jun 30, 2025
INTEGRATED CORE STRATEGIES (US) LLC 5.3% -8.33% $8.48M $2.7M 2.84M +46.7% Millennium Management LLC Jun 30, 2025
MIZUHO FINANCIAL GROUP INC 6.6% +13.3% $3.94M $496K 2.2M +14.4% Mizuho Financial Group, Inc. Mar 31, 2025
BlackRock, Inc. 5.5% $3.26M 1.82M BlackRock, Inc. Dec 31, 2024
EVENTIDE ASSET MANAGEMENT, LLC 3.73% $2.21M 1.23M Eventide Asset Management, LLC Dec 31, 2024
Omega Fund VI, L.P. 3.6% $2.12M 1.18M Omega Fund VI, L.P. Dec 31, 2024
D1 Capital Partners L.P. 2.9% $1.75M 979K D1 Capital Partners L.P. Mar 31, 2025
Adage Capital Management, L.P. 0.7% -85.4% $426K -$3.53M 238K -89.2% Adage Capital Management, L.P. Mar 31, 2025

Institutional Holders of Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q2 42.3M $170M +$59M $4.02 90
2025 Q1 28M $100M -$11.5M $3.47 88
2024 Q4 29.5M $194M -$4.09M $6.58 89
2024 Q3 29.7M $269M +$10.3M $9.04 67
2024 Q2 26.6M $426M +$55.3M $16.04 57
2024 Q1 23.1M $362M +$108M $15.68 54
2023 Q4 16.2M $217M +$217M $13.42 31